Bath, United Kingdom

John Nicholas Staniforth

This inventor holds 83 USPTO granted patents and 6 published patent applications, plus 5 CIPO patents and 14 EPO patents, primarily in Pharmaceutical Formulations (CPC class A61K9-0075). Top assignees: Vectura Gmbh, Edward Mendell Co., Inc., Pharmakodex Limited. Active years: 1989-2021.

USPTO Granted Patents = 83 

% Patents Active = 50.6

 

 

Average Co-Inventor Count = 2.2

ph-index = 29

Forward Citations = 2,274(Granted Patents)

Forward Citations (Not Self Cited) = 2,004(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Bath, GB (1989 - 2017)
  • Chippenham, GB (2010 - 2021)
  • Wiltshire, GB (2011 - 2021)

Company Filing History:

goldMedal33 out of 71 
 
Vectura Gmbh
 patents
silverMedal18 out of 47 
 
Edward Mendell Co., Inc.
 patents
bronzeMedal3 out of 3 
 
Pharmakodex Limited
 patents
4. 3 out of 7 
 
Phoqus Pharmaceuticals Limited
 patents
5. 3 out of 9 
 
Sosei R&d Ltd.
 patents
6. 2 out of 2 
 
Andi-Ventis Limited
 patents
7. 2 out of 11 
 
Britannia Pharmaceuticals Limited
 patents
8. 2 out of 12 
 
Hoechst (UK) Limited
 patents
9. 2 out of 4 
 
J. Rettenmaier & Soehne Gmbh & Co. Kg
 patents
10. 2 out of 11 
 
Penwest Pharmaceuticals Company
 patents
11. 2 out of 157 
 
Ranbaxy Laboratories, Inc.
 patents
12. 2 out of 51 
 
The University of Bath
 patents
13. 1 out of 1 
 
Co-Ordinated Drug Development Limited
 patent
14. 1 out of 1,597 
 
Conopco, Inc.
 patents
15. 1 out of 1 
 
Forum Chemicals Ltd.
 patent
16. 1 out of 1 
 
J. Rettenmaier & Soehne Gmbh + Co. Kg
 patent
17. 1 out of 4 
 
Phoqus Limited
 patents
18. 1 out of 1 
 
University of Bath (British Corp.)
 patent
19. 1 out of 1 
 
Vectura Drug Delivery
 patent
20. 1 out of 1 
 
Vectura Limited (01696917)
 patent
21. 1 out of 834,453 
Other
 patents

Years Active: 1989-2021

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Pharmaceutical Compositions
Inhalation Therapies
Particle Manufacturing
Dry Powder Inhalers
Microparticles
Carrier Particles
Controlled Release
Mucoactive Agents
Topical Formulations
Respiratory Diseases
Anti-asthmatic Combinations
Oral Drug Delivery
83 patents (USPTO):Explore Patents

Title: John Nicholas Staniforth: Pioneering Pharmacist Inventor

Introduction:

John Nicholas Staniforth, hailed from Bath, GB, is a prolific inventor in the field of pharmaceutical compositions with an impressive 37 patents to his name. His groundbreaking work has revolutionized the way inhalable pharmaceutical compositions are prepared and utilized.

Latest Patents:

One of Staniforth's latest patents includes a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration. This method involves a milling step that enhances the dispersal of the composite active particles upon inhaler actuation. Another significant patent is a method for creating composite excipient particles for inhalable pharmaceutical compositions, which boasts small size product particles with low energy input during milling.

Career Highlights:

Staniforth has left an indelible mark on the pharmaceutical industry through his tenure at innovative companies such as Vectura Gmbh and Pharmakodex Limited. His relentless pursuit of excellence and unwavering dedication to advancing pharmaceutical technologies have earned him a reputable position in the field.

Collaborations:

Throughout his career, Staniforth has collaborated with esteemed professionals in the field, including David Alexander Vodden Morton and Rossella Musa. These collaborations have led to the development of cutting-edge pharmaceutical inventions and propelled the industry forward.

Conclusion:

John Nicholas Staniforth's ingenuity and commitment to innovation have significantly impacted the pharmaceutical landscape. His patents and collaborations stand as a testament to his remarkable contributions to the field of pharmaceutical compositions, inspiring future generations of inventors to push the boundaries of what is possible in healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…